Study
Cannabidiol Reduces Seizures in Lennox-Gastaut Syndrome Patients
Adding cannabidiol to standard epilepsy treatment reduced drop seizures by over 40% in patients with Lennox-Gastaut syndrome.
Summary
In plain language
Researchers have found that adding cannabidiol, a compound derived from cannabis, to the existing treatment plans of individuals with Lennox-Gastaut syndrome significantly reduced the frequency of drop seizures. In the study, patients who received cannabidiol experienced a reduction of about 42% in drop seizures, compared to a 17% reduction with a placebo. This finding is important as it offers hope for better seizure management in individuals with this challenging form of epilepsy. Seniors living with or caring for someone with Lennox-Gastaut syndrome might find this information valuable when discussing treatment options with their healthcare providers.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
The study was a well-controlled trial involving 225 participants with Lennox-Gastaut syndrome, a severe epilepsy disorder. Participants were divided into groups receiving either a high dose, a low dose of cannabidiol, or a placebo, in addition to their usual medication.
The high-dose cannabidiol group saw a 41.9% reduction in drop seizures, while the low-dose group saw a 37.2% reduction, both significantly higher than the placebo group's 17.2% reduction.
Common side effects included sleepiness and decreased appetite, with some participants experiencing liver enzyme changes.
While promising, it's essential to consider potential side effects and consult a healthcare provider to evaluate if this treatment fits individual health needs.
Discussing these findings with a healthcare provider can help determine if cannabidiol could be a beneficial addition to one's treatment plan.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
Cannabidiol Reduces Seizures in Lennox-Gastaut Syndrome Patients
Published September 2026
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored September 27, 2026 using rubric mq-1.8_2026-07-06.
Assessment
The study scored highly due to its rigorous RCT design, comprehensive bias control, and robust statistical methods. Transparency was strong with pre-registration and protocol availability. However, conflicts of interest were not fully transparent, and the study's relevance to seniors was limited by the broad age range without specific subgroup analysis.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 10.0/10 | |
| Bias control | 10.0/10 | |
| Statistical methods | 10.0/10 | |
| Reporting completeness | 10.0/10 | |
| Conflicts & funding | 2.5/10 | |
| Replication | 5.0/10 | |
| Relevance to chosen population | 5.0/10 | |
| Journal Reliability | 5.0/10 |
Additional Notes
This RCT evaluated the efficacy and safety of cannabidiol in reducing drop seizures in Lennox-Gastaut syndrome patients aged 2-55. Cannabidiol significantly reduced seizure frequency compared to placebo, with common adverse events including somnolence and elevated liver enzymes.
Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were reviewed.
Treatments Evaluated in This Research
Review the interventions studied here and compare them against the broader treatment library.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.